Relegent

Relegent is a biotechnology company dedicated to developing next-generation small molecule therapeutics for cardiovascular diseases, with a primary focus on heart failure. Founded by industry veterans from MyoKardia and backed by Third Rock Ventures, the company leverages deep expertise in cardiac muscle biology to address the underlying mechanical drivers of cardiac dysfunction. Relegent's research centers on modulating sarcomere proteins, such as cardiac myosin, to improve heart function in patients with both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The company aims to provide precision medicine approaches to diverse patient populations that currently have limited treatment options.